HC Wainwright Estimates Altimmune’s Q3 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT) – HC Wainwright raised their Q3 2026 earnings per share estimates for Altimmune in a report released on Monday, August 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.15). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Altimmune’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.39) EPS and FY2030 earnings at ($0.15) EPS.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative return on equity of 31.41% and a negative net margin of 214,860.98%.

Other analysts also recently issued reports about the stock. Citizens Jmp cut their price objective on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th. Finally, Leerink Partners assumed coverage on shares of Altimmune in a research report on Monday, June 22nd. They set an “outperform” rating and a $10.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Altimmune currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Altimmune Price Performance

ALT opened at $2.97 on Wednesday. The firm has a market cap of $577.58 million, a PE ratio of -3.81 and a beta of 0.27. The stock has a 50-day moving average price of $2.91 and a 200-day moving average price of $3.34. Altimmune has a 1 year low of $2.56 and a 1 year high of $6.44. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78.

Hedge Funds Weigh In On Altimmune

Hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP raised its holdings in shares of Altimmune by 356.6% during the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after purchasing an additional 1,559,562 shares during the last quarter. State Street Corp boosted its holdings in Altimmune by 42.2% in the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock worth $18,482,000 after purchasing an additional 1,518,448 shares during the last quarter. Vanguard Group Inc. grew its position in Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after purchasing an additional 1,206,514 shares during the period. Nuveen LLC grew its position in Altimmune by 514.9% in the 4th quarter. Nuveen LLC now owns 1,244,211 shares of the company’s stock worth $4,492,000 after purchasing an additional 1,041,856 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Altimmune during the 4th quarter valued at $3,331,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Key Stories Impacting Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.56 from $0.63 and its FY2027 estimate to a loss of $0.63 from $0.80. The firm also improved estimates for several quarterly periods, including Q3 and Q4 2026 and Q1–Q4 2027. Altimmune analyst estimates
• Positive Sentiment: Longer-term forecasts were also upgraded: FY2028 EPS improved to a loss of $0.63 from $1.02, FY2029 to a loss of $0.39 from $0.55, and FY2030 to a loss of $0.15 from $0.32. These changes suggest the analyst expects Altimmune’s path toward profitability to be better than previously anticipated. Altimmune long-term earnings estimates
• Neutral Sentiment: Despite the upgrades, HC Wainwright still expects Altimmune to remain unprofitable through 2030, with a projected FY2027 loss of $0.63 per share and a FY2026 consensus loss of $0.60. Investors will continue to focus on clinical progress, funding needs and the company’s ability to convert its pipeline into commercial revenue.
• Negative Sentiment: Altimmune remains a loss-making biotechnology company, with a negative PE ratio and substantial negative net margin. The revised forecasts reduce expected losses but do not yet represent projected earnings or confirmed profitability.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.